Phospho-Estrogen Receptor alpha (Ser305)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 5338R
英文名称Phospho-Estrogen Receptor alpha (Ser305)
中文名称磷酸化雌**受体α抗体
别 名Estrogen Receptor alpha (phospho S305); p-Estrogen Receptor alpha (phospho S305); ER alpha (Phospho-Ser305); ER alpha (Phospho-S305); Phospho-ER alpha (S305); Phospho-ER alpha (Ser305); p-ER alpha (Ser305); p-ER alpha (S305); Phospho-Estrogen Receptor alpha (S305); Phospho-Estrogen Receptor alpha (S305); Estradiol receptor; Estrogen receptor alpha; Estradiol Receptor-alpha; Estrogen Receptor 1; Atherosclerosis, susceptibility to, included; DKFZp686N23123; ER Alpha; ER; ER-alpha; ERalpha; ER[a]; Era; ESR; ESR1; ESR1_HUMAN; ESR2; ESRA; Estr; Estrogen receptor 1 (alpha); Estrogen resistance, included; HDL cholesterol, augmented response of, to hormone replacement, included; Myocardial infarction, susceptibility to, included; NR3A1; Nuclear receptor subfamily 3 group A member 1; OTTHUMP00000017718; OTTHUMP00000017719; RNESTROR.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 染色质和核信号 神经生物学 信号转导 表观遗传学
抗体来源Rabbit
克隆类型Polyclonal
Phospho-Estrogen Receptor alpha (Ser305)抗体交叉反应 Human, Mouse,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg/Test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量66kDa
细胞定位细胞核 细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human Estrogen Receptor alpha around the phosphorylation site of Ser305:KN(p-S)LA
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-Estrogen Receptor alpha (Ser305)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
Estrogen and progesterone receptor are members of a family of transcription factors that are regulated by the binding of their cognate ligands. The interaction of hormone-bound estrogen receptors with estrogen responsive elements(EREs) alters transcription of ERE-containing genes. The carboxy terminal region of the estrgen receptor contains the ligand binding domain, the amino terminus serves as the transactivation domain, and the DNA binding domain is centrally located. Two forms of estrogen receptor have been identified, ER alpha and ER beta. ER alpha and ER beta have been shown to be differentially activated by various ligands. The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (hPR-A and hPR-B), which arise from alternative splicing. In most cells, hPR-B functions as a transcriptional activator of progesterone-responsive gene, whereas hPR-A function as a transcriptional inhibitor of all steroid hormone receptors.
Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.
Subunit:
Binds DNA as a homodimer. Can form a heterodimer with ESR2. Isoform 3 can probably homodimerize or heterodimerize with isoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1C and NCOA3 coactivator (By similarity). Interacts with EP300; the interaction is estrogen-dependent and enhanced by CITED1. Interacts with CITED1; the interaction is estrogen-dependent. Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7; the interaction is a ligand-inducible. Interacts with PHB2, PELP1 and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interacts with KDM5A. Interacts with SMARD1. Interacts with HEXIM1. Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7 beta-estradiol (E2) and enhances ERS1-mediated transcription. Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform 4 of TXNRD1. Interacts with MLL2. Interacts with ATAD2 and this interaction is enhanced by estradiol. Interacts with KIF18A and LDB1. Interacts with RLIM (via C-terminus). Interacts with MACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4A blocks binding to PLCG and inhibits estrogen-induced cell proliferation. Interacts with DYNLL1. Interacts with CCDC62 in the presence of estradiol/E2; this interaction seems to enhance the transcription of target genes. Interacts with NR2C1; the interaction prevents homodimerization of ESR1 and suppresses its transcriptional activity and cell growth. Interacts with DYX1C1. Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC and PTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only in the presence of SAV1 and vice-versa. Binds to CSNK1D. Interacts with NCOA2; NCOA2 can interact with ESE1 AF-1 and AF-2 domains simultaneously and mediate their transcriptional synergy. Interacts with DDX5. Interacts with NCOA1; the interaction seems to require a self-association of N-terminal and C-terminal regions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3. Interacts with NRIP1 (By similarity).
Subcellular Location:
Isoform 1: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=A minor fraction is associated with the inner membrane.
Isoform 3: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell membrane; Single-pass type I membrane protein. Note=Associated with the inner membrane via palmitoylation (Probable). At least a subset exists as a transmembrane protein with a N-terminal extracellular domain.
Nucleus. Golgi apparatus. Cell membrane. Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated.
Tissue Specificity:
Widely expressed. Isoform 3 is not expressed in the pituitary gland.
Post-translational modifications:
Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably enhances transcriptional activity. Self-association induces phosphorylation.
Glycosylated; contains N-acetylglucosamine, probably O-linked.
Ubiquitinated. Deubiquitinated by OTUB1.
Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization.
Palmitoylated (isoform 3). Not biotinylated (isoform 3).
Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor.
Similarity:
Belongs to the nuclear hormone receptor family. NR3 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
Gene ID:
2099
Phospho-Estrogen Receptor alpha (Ser305)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-Estrogen Receptor alpha (Ser305)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 GAGE7 肿瘤/睾丸抗原家族4亚型7抗体
合格 LRRC15 富含亮氨酸重复蛋白15抗体
合格 MAGEA11 黑色素瘤相关抗原11抗体
合格 MAGEB3 黑色素瘤相关抗原B3抗体
合格 MAGEB6 黑色素瘤相关抗原B6抗体
合格 PDCD7 凋亡相关蛋白7抗体
合格 IL-4I1 白细胞介素4诱导蛋白1抗体
合格 TPST1 酪蛋白硫酸转移酶1抗体
合格 Alpha 1 Acid Glycoprotein α1酸性糖蛋白1/类粘蛋白1抗体
合格 合格 PIWIL4 piwi样4蛋白抗体
合格 NALP6 富含亮氨酸重复结构域蛋白6抗体
合格 ILP2 抑制细胞凋亡样蛋白2抗体
合格 RING finger protein 189 环指蛋白189抗体
合格 合格 Catalase 过氧化氢酶抗体
合格 CCBR1 钙离子通道阻端耐药蛋白CCBR1抗体
合格 WDR61 WD重复膜蛋白61抗体
合格 GMCL1L 生殖细胞样蛋白1样蛋白抗体
合格 Fibrinogen gamma chain 纤维蛋白原γ链抗体
合格 Fibrinopeptide B 纤维蛋白肽B/血纤肽B抗体
合格 PRC1 胞质分裂调控蛋白1抗体
合格 CDCREL 细胞周期调控相关蛋白1
合格 CCDC5 卷曲螺旋结构域蛋白5抗体
合格 合格 BMP9 骨形态发生蛋白9抗体
合格 CCDC69 卷曲螺旋结构域蛋白69抗体
合格 CCDC98 卷曲螺旋结构域蛋白98抗体
合格 CCDC90A 卷曲螺旋结构域蛋白90A抗体
合格 CD81 CD81抗体
合格 RNF74 环指蛋白74抗体（重组激活基因1）
合格 POMC 阿黑皮素原抗体
合格 合格 AKT1+2+3 蛋白激酶AKT1,2,3抗体
合格 LPAP **细胞磷蛋白磷酸酶相关蛋白抗体
合格 SEMA4D 跨膜蛋白SEMA4D抗体
合格 HLA DM 组织相容性复合体α抗体
合格 FOXN1 叉头蛋白N1抗体
合格 Mkl1 myocardin相关转录因子抗体